CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) will announce its first quarter 2005 financial
results on May 5, 2005 before the open of U.S. financial markets. In
connection with this announcement, TKT will host a conference call and live
audio webcast on May 5, 2005 at 10:00 a.m. Eastern Time to discuss its first
quarter 2005 financial results, the company's business activities, and
financial outlook.
Participants may access the call by dialing (719) 457-2642. This call will
also be broadcast live over the Internet at http://www.tktx.com under the
Investor Information section. Please dial in 5 to 10 minutes prior to the
scheduled conference call time or log on to the website at least 15 minutes
prior to the call in order to register, download, and install any necessary
software.
A replay of the conference call and webcast will be available once a
transcript has been filed with the Securities and Exchange Commission.
Participants may access this replay by dialing (719) 457-0820 and using the
access code 2495707. In addition, a replay of the webcast will be archived on
the TKT website under Events in the Investor Information section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
For More Information Contact:
Daniella M. Lutz
Manager, Corporate Communications
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Manager, Corporate
Communications of TKT, +1-617-349-0205
|
